Drug Trial Radar · NCT07606521
A Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus
Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
222
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Dec 2027
Study completion Apr 2028
Sponsor
- Lead sponsor
- Polpharma Biologics International AGIndustry
- Sponsor type
- Industry
- First posted
- May 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, parallel group, double-blind, active-controlled, clinical pharmacology study to compare Pharmacokinetics, Pharmacodynamics and safety of PB018 versus Ocrevus in patients with Multiple Sclerosis.
Conditions
- Multiple Sclerosis
Interventions
US-OcrevusBiological
Intravenous(IV) infusion
PB018Biological
Intravenous(IV) infusion
EU-OcrevusBiological
Intravenous(IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the concentration time curveTime frame: Week 0 to Week 24
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.